LAVA Therapeutics N.V.

NASDAQ:LVTX

0.9752 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q32019 Q22019 Q1
Revenue 006.9920.3530.0535.1391.2242.6415.2610.4681.0221.0662.0951.0811.7640.970.6650000
Cost of Revenue 00.22800.1540.012.3880.9300006.6346.7034.89518.7124.3223.863.4543.235000
Gross Profit 0-0.2286.9920.1990.0432.7510.2942.6415.2610.4681.022-5.568-4.608-3.815-17.712-2.558-2.89-2.789-3.235000
Gross Profit Ratio 0010.5640.8110.5350.241111-5.223-2.2-3.532-17.712-1.45-2.981-4.1930000
Reseach & Development Expenses 8.56.3366.0093.367.91212.5999.94310.5413.6978.3717.4976.6346.7034.89518.7124.3223.863.4543.2352.0432.1212.097
General & Administrative Expenses 2.7853.0252.9352.2812.8583.6973.893.5793.1353.1734.2373.7683.762.7641.7270.2570.7740.7550.7520.3040.3150.312
Selling & Marketing Expenses 0000000000000000000000
SG&A 2.7853.0252.9352.2812.8583.6973.893.5793.1353.1734.2373.7683.762.7641.7270.2570.7740.7550.7520.3040.3150.312
Other Expenses 0000000000000000000-4.698-4.876-4.823
Operating Expenses 11.2859.3618.2867.4829.63816.05214.7817.95914.3178.40810.6222.4432.1234.0031.8770.0450.9421.0480.759-2.351-2.44-2.414
Operating Income -11.285-9.361-1.952-5.442-10.727-13.545-13.539-11.479-1.571-11.076-10.712-9.336-8.368-6.579-19.439-2.815-3.664-3.544-3.986-2.351-2.44-2.414
Operating Income Ratio 00-0.279-15.416-202.396-2.636-11.061-4.348-0.103-23.667-10.481-8.758-3.994-6.092-19.439-1.595-3.779-5.3280000
Total Other Income Expenses Net -0.9151.151.468-0.9951.9410.942-0.33-3.452.5543.0460.949-0.4571.479-1.426-0.279-1.514-0.271-0.354-0.064-0.021-0.022-0.022
Income Before Tax -12.2-8.211-0.484-6.437-8.786-12.603-13.869-14.8480.983-8.03-9.763-8.162-6.889-8.005-19.718-2.61-3.94-3.902-4.05-2.373-2.463-2.436
Income Before Tax Ratio 00-0.069-18.235-165.774-2.452-11.331-5.6240.064-17.158-9.553-7.657-3.288-7.412-19.718-1.48-4.063-5.8650000
Income Tax Expense 0.0960.0850.0690.0610.050.0970.0710.0670.0470.0760.0590.0570.0440.0320.0240.04300.0030.0030.0210.0220.022
Net Income -12.296-8.296-0.553-6.498-8.836-12.7-13.94-14.9150.936-8.106-9.822-8.219-6.933-8.037-19.742-2.653-3.94-3.898-4.053-2.394-2.485-2.458
Net Income Ratio 00-0.079-18.408-166.717-2.471-11.389-5.650.061-17.321-9.611-7.71-3.309-7.442-19.742-1.504-4.063-5.860000
EPS -0.46-0.31-0.021-0.24-0.34-0.48-0.53-0.570.036-0.31-0.38-0.32-0.27-0.31-12.14-9.44-9.37-8.71-9.06-0.131-0.136-0.135
EPS Diluted -0.46-0.31-0.021-0.24-0.34-0.48-0.53-0.570.036-0.31-0.38-0.32-0.27-0.31-12.14-9.44-9.37-8.71-9.06-0.131-0.136-0.135
EBITDA -11.073-9.241-1.808-5.259-10.575-13.393-13.226-11.29-1.466-10.967-10.611-9.24-8.281-6.723-19.368-3.866-3.601-3.494-3.946-2.288-2.374-2.348
EBITDA Ratio 00-0.259-14.898-199.528-2.606-10.956-4.277-0.096-23.434-10.383-8.668-3.953-6.02-19.368-1.568-3.713-5.2520000